Abstract:Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Dekker grant Aortic stenosis (AS) is a narrowing of the aortic valve opening due to calcification and valve thickening. There are currently no pharmacological treatments for AS, and surgical interventions are the only therapies. To understand the molecular mechanisms underlying AS and test new pharmacological agents, advanced calcification models are required. These models need to closely approach native tissue response to stimuli by maintaining the valvular interstitial cells within their native environment. We have recently developed an ex vivo culture model that fulfills this requirement and allows the induction of calcification in slices of human aortic valves. Our goal is to evaluate the applicability of our ex-vivo calcification model as a pre-clinical test system for potential therapies. Diseased aortic valves were dissected, embedded in agarose, then cut into 300-500 um slices using a vibratome. The use of multiple slices from a single patient ensured proper internal controls. To induce calcification, slices were cultured with 3mM phosphate(n=12), and control slices without phosphate (n=11). To investigate molecular modulation of induced calcification, dexamethasone was added to phosphate cultures(n=9). The slices were assessed for calcification using Alizarin Red staining. ImageJ was used to quantify the percentage of alizarin red-positive area. The average thickness was determined using 3DHISTECH software. In the presence of phosphate, a significant increase in the calcification percentage was observed in cultured valve slices compared with cultures without phosphate (p<0.05). Interestingly, within the phosphate-treated group, two sub-groups could be distinguished, one sub-group exhibiting extensive calcification, while the other showed virtually no sign of calcification. Paired comparisons revealed strong effect of dexamethasone depending on the extent of calcification-inducing capability of phosphate in each patient-sample. More precisely, dexamethasone exhibited potent inhibitory effect on calcification in valvular slices from patients where calcification was stimulated in the presence of phosphate. Conversely, dexamethasone exhibited a stimulatory effect on calcification in slices that did not show a stimulation of calcification in the presence of phosphate. This differential effect was strongly correlated with valve thickness.(r=-0.884,p< 0.01). Our novel ex-vivo calcification model for human aortic valves revealed potential presence of patient-specific effects of pharmacological agents. Dexamethasone can have both stimulatory and inhibitory effects on calcification levels, influenced by phosphate response and valve thickness. As thickness might be indicative of the disease stage, this correlation suggests that the direction of compound's effect might depend on disease stage. Hence, proper understanding of potential opposite effects of compounds is crucial in developing novel therapies.

Novel bisphosphonate compound FYB-931 preferentially inhibits aortic calcification in vitamin D3-treated rats

Effect of crystallization inhibitors on vascular calcifications induced by vitamin D: a pilot study in Sprague-Dawley rats

Mechanism of action of SNF472, a novel calcification inhibitor to treat vascular calcification and calciphylaxis

Inhibitory Effect of Ginkgo Biloba Extract on Vascular Calcification in Rats with Chronic Kidney Disease by ROS-NF-κB Signaling Pathway

SNF472: a novel therapeutic agent for vascular calcification and calciphylaxis

Lead Acetate-Injected Mice is an Animal Model for Extrapolation of Calcifying Response to Humans Due to Low Involvement of Bone Resorption

Farnesyl pyrophosphate synthase inhibitors with antiosteoporosis efficacy in ovariectomized rats: A mixed binding approach beyond bisphosphonates

Daily peritoneal administration of sodium pyrophosphate in a dialysis solution prevents the development of vascular calcification in a mouse model of uraemia

κ-opioid receptor stimulation alleviates rat vascular smooth muscle cell calcification via PFKFB3-lactate signaling

Febuxostat attenuates vascular calcification induced by vitamin D3 plus nicotine in rats

Seaweed Porphyra yezoensis polysaccharides with different molecular weights inhibit hydroxyapatite damage and osteoblast differentiation of A7R5 cells.

Immobilized Bisphosphonates as Potential Inhibitors of Bioprosthetic Calcification: Effects on Various Xenogeneic Cardiovascular Tissues

Short-term therapy with R568 ameliorated secondary hyperparathyroidism but does not prevent aortic valve calcification in uremic rats

Endogenous Calcification Inhibitors in the Prevention of Vascular Calcification: A Consensus Statement From the COST Action EuroSoftCalcNet

Comparison of the Inhibitory Mechanisms of Diethyl Citrate, Sodium Citrate, and Phosphonoformic Acid on Calcification Induced by High Inorganic Phosphate Contents in Mouse Aortic Smooth Muscle Cells

Combining phosphate binder therapy with vitamin K2 inhibits vascular calcification in an experimental animal model of kidney failure

Novel ex-vivo calcification model for human aortic valves reveals patient-specific effect of compound

Platelet Membrane-Coated Alterbrassicene a Nanoparticle Inhibits Calcification of the Aortic Valve by Suppressing Phosphorylation P65 NF-κB

A Low Concentration of Citreoviridin Prevents Both Intracellular Calcium Deposition in Vascular Smooth Muscle Cell and Osteoclast Activation In Vitro

[Therapeutic agents for disorders of bone and calcium metabolism: Minodronic acid hydrate]

[The Effect of Alendronate on Arterial Calcification in Rat Model].